blocks two different signaling pathways (IL-4 and IL-13) that drive Type 2 (allergic and eosinophilic) inflammation. Anti-TSLP Therapy: Tezepelumab (Tezspire)
These are not anomalies. They are the direct result of knowing the pathway. Sevreasthmamedicationtreatmentoption -FREE-
| Medication | Manufacturer | PAP Name | Free drug eligibility | |------------|--------------|----------|------------------------| | Dupixent (dupilumab) | Sanofi/Regeneron | Dupixent MyWay | Uninsured or commercial insurance + income ≤ 400% FPL | | Nucala (mepolizumab) | GSK | GSK Patient Assistance Program | Uninsured, income ≤ 200% FPL | | Fasenra (benralizumab) | AstraZeneca | AZ&Me | Uninsured, income ≤ 300% FPL | | Xolair (omalizumab) | Novartis/Genentech | Xolair Copay & Patient Assistance | Varies; some receive $0 cost | | Tezspire (tezepelumab) | Amgen/AstraZeneca | Tezspire Patient Support | Case-by-case | blocks two different signaling pathways (IL-4 and IL-13)
Severe asthma can be caused by a variety of factors, including: | Medication | Manufacturer | PAP Name |
Severe asthma management has transformed from blanket high-dose ICS/OCS to precision medicine using biologics. First-line add-on biologics should be selected by phenotype, with dupilumab emerging as highly effective for Type 2 inflammation. Non-biologic options like azithromycin and thermoplasty remain valuable in specific phenotypes. All patients should have a written asthma action plan and regular review by a specialist.
Severe asthma is characterized by symptoms that persist—such as daily coughing, nighttime awakenings, or frequent ER visits—even when a patient is using standard high-dose inhaled corticosteroids (ICS) and long-acting beta-agonists (LABA).